Domain name dispute to win over potential phishing domain (UDRP)

"Groth & Co handled the case fast, efficient and with great expertise. We are pleased with the outcome."
DATE
Nov 2019
CLIENT
Recipharm AB (publ)
INDUSTRY
Life Science
WORKFLOW

Domain Name
Litigation
Watching

Services

Recipharm is a listed Swedish pharmaceutical company with global operations

Recipharm is a leading pharmaceutical contract development and manufacturing organisation (CDMO) headquartered in Stockholm with over 6000 employees globally. The company is listed on Mid Cap Stockholm and we have been assisting Recipharm with trademarks and domain names since 2001.

A third-party registered secured-recipharm.com

Using our domain name watching service, we found that an unknown third-party had registered the domain name secured-recipharm.com. When we found it, there was no website published under the domain but Recipharm suspected that the domain could be used for phishing or other fraudulent activities. Therefore, we were instructed to take down the domain name.

Through a domain dispute resolution procedure (UDRP), we got the domain transferred to Recipharm

Our efforts started with contacting the registrar, asking them to take down the domain name. Yet, the registrar took no action despite of our argumentation and reminders. Therefore, we filed a request for a UDRP (Uniform Domain-Name Dispute-Resolution Policy) at WIPO to try to get the domain name transferred to our client. We handled this procedure for Recipharm, including drafting and filing of written argumentation on why the domain name should be transferred to our client. This was mainly based on referencing the clients existing trademark rights for Recipharm.

We were successful in the UDRP, and the domain name was therefore transferred to our client. The domain could therefore no longer be used for fraudulent attempts against our client. The dispute resolution through UDRP took less than two months and the fee to official fee for an UDRP is only $1500.

Groth & Co handled the case fast, efficient and with great expertise. We are pleased with the outcome.
/Martina Ferneman, Director of Corporate Development, Recipharm

CONTACTS

Carl Wendt

Partner
Deputy Head of Legal and Trademark Dept.
European Trademark and Design Attorney

More cases

ContextVision AB

Patent strategy for Artificial Intelligence in MedTech

READ MORE

Pfizer Inc.

Global assignment of approx. 25,000 assets for Pfizer

READ MORE